Tag: bard
e-PTFE covered stent demonstrates “significantly better” target lesion primary patency compared...
The results of AVeNEW, the first level one clinical study dedicated solely to the use of a covered stent designed to treat stenosis in...
BD acquires TVA Medical, makers of everlinQ endoAVF System
BD (Becton, Dickinson and Company) announced it has completed the acquisition of TVA Medical, a company that develops minimally invasive vascular access solutions...
BD announces completion of enrolment in Lutonix 014 DCB below-the-knee trial
Enrolment is complete in the Lutonix below-the-knee trial with BD planning to submit a pre-market approval application to the US Food and Drug Administration...
BD completes acquisition of Bard
BD, a leading global medical technology company, has announced it has completed the acquisition of C R Bard, creating a new health care industry...
European Commission approves BD acquisition of Bard, subject to conditions
The European Commission has approved, under the EU Merger Regulation, the acquisition of Bard by BD. The decision is conditional on the divestment of...
Bard gets FDA premarket approval of the Lutonix 035 DCB for...
Bard’s Lutonix 035 drug-coated balloon PTA catheter (DCB) has been granted premarket approval (PMA) by the US Food and Drug Administration (FDA) for a...
Covera Plus covered stent receives the CE mark
Bard Peripheral Vascular has announced it has received CE marking to market the Covera Plus covered stent.
According to Bard, with the new Covera Plus...
Lutonix for dysfunctional arteriovenous fistulae shows improved primary patency vs. plain...
Interim twelve-month data from the Lutonix AV Clinical Trial indicate that treatment of dysfunctional arteriovenous (AV) fistulae with Bard’s Lutonix drug-coated balloon (DCB) produces...
BD to acquire Bard for US$24 billion
BD (Becton, Dickinson and company) has definitively agreed to acquire Bard for US$317 per common share in cash and stock, for a total consideration...
Lutonix AV results provide tailwind for drug-coated balloons in dysfunctional arteriovenous...
Scott Trerotola presented the first release of eight-month data from the Lutonix AV trial at the Leipzig Interventional Course (LINC; 24–27 January, Leipzig, Germany)...
Global cohorts report drug-coated balloon success above the knee and “promising”...
Three global registries reported fresh data at the 2017 Leipzig Interventional Course (LINC; 24–27 January, Leipzig, Germany), all of which showed encouraging outcomes for...
Promising early results for Lutonix US IDE trial in obstructed AV...
The first US randomised controlled trial for drug-coated balloon use for arteriovenous fistula obstructions for 50 years, the Lutonix (Bard) IDE trial was a...
Lutonix Global Real-World Registry 24-month outcomes presented at VIVA 2016
Bard has announced the presentation of the final 24-month results from the Lutonix Global Real-World Registry at the Vascular Intervention Advances (VIVA) 2016 meeting...
FDA approves six-month primary endpoint for the Lutonix below-the-knee drug-coated balloon
The US Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) supplemental application to modify the primary endpoint to a six-month...
UK NICE publishes Medtech Innovation Briefing on Lutonix
The UK National Institute for Health and Care Excellence (NICE) has developed a Medtech Innovation Briefing (MIB) on the Lutonix drug-coated balloon (DCB) for...
